Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts projected.

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday, a new ...

Novo Nordisk’s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its ...

The maker of Ozempic is facing stiff competition from rival obesity drug companies, as well as unproven knock-offs from China ...

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

Shares in Novo Nordisk opened sharply lower on Wednesday, after the obesity drug specialist warned of thinning sales and profits.

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...